This cluster groups 2 independently calculated changes: Cash & equivalents increased 45.4%; Operating cash flow increased 8.2%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTMetagenomi Therapeutics, Inc.'s latest supported as-filed period reports revenue of $1.2M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 45.4%; Operating cash flow increased 8.2%.
2 evidence-backed componentsOperating income changed -37.1% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
MGX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-389550SEC ↗4Sep 10, 2026Period Sep 8, 20260001193125-26-387816SEC ↗4Sep 10, 2026Period Sep 8, 20260001193125-26-387798SEC ↗4Sep 10, 2026Period Sep 8, 20260001193125-26-387786SEC ↗10-QAug 10, 2026Period Jun 30, 20260001193125-26-342400SEC ↗8-KAug 10, 2026Period Aug 10, 20260001193125-26-342388SEC ↗4Jun 11, 2026Period Jun 9, 20260001193125-26-267272SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 9, 2026Filed Sep 11, 2026 | Reid LaurenceDirector | Open Market PurchaseDirect | 19,883 | $1 | $23,263 | Form 4 ↗ |
| Sep 9, 2026Filed Sep 11, 2026 | Reid LaurenceDirector | Open Market PurchaseDirect | 117 | $1 | $138 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Wapnick PamelaChief Financial Officer | Open Market SaleDirect | 1,911 | $1 | $2,214 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Irish JianSee Remarks | Open Market SaleDirect | 2,140 | $1 | $2,479 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Current ratio changed -29.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Cash & equivalents changed +45.4% from the comparable as-filed period.
Current assets changed -41.2% from the comparable as-filed period.
Total assets changed -36.2% from the comparable as-filed period.
Trade receivables changed -100.0% from the comparable as-filed period.
Working capital / assets changed -978 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-267255| Wein MatthewSee Remarks |
| Open Market SaleDirect |
| 358 |
| $1 |
| $415 |
| Form 4 ↗ |
| Jun 9, 2026Filed Jun 11, 2026 | Reid LaurenceDirector | Grant Or AwardDirect | 17,400 | $0 | $0 | Form 4 ↗ |